Table 3.

Associations of KRAS G12/G13 MAF in ctDNA with clinicopathological data of NSCLC patients.

Variable	No. of Patients	Mean ± S.E. a	Range	p-Value
TNM Stage b				0.213 c
III	24	0.34 ± 0.17	0.0–3.89
IV	88	2.06 ± 0.56	0.0–28.27
Smoking status
Non-smokers	7	0.05 ± 0.03	0.0–0.21	0.135 d
Former smokers	33	3.07 ± 1.06	0.0–28.27
Smokers	68	1.41 ± 0.53	0.0–26.14
PD-L1 status
Negative	37	1.01 ± 0.38	0.0–8.59	0.239 c
Positive	45	2.23 ± 0.84	0.0–26.14
Histologic type
Adenocarcinoma	91	1.85 ± 0.46	0.0–26.14	0.183 d
Squamous cell carcinoma	15	0.17 ± 0.06	0.0–0.67
Other	8	3.54 ± 3.53	0.0–28.27
Performance status e
0	86	1.29 ± 0.37	0.0–19.62	0.379 c
1 or 2	27	3.27 ± 1.43	0.0–28.27
Gender
Males	92	1.38 ± 0.41	0.0–28.27	0.361 c
Females	22	3.27 ± 1.49	0.0–26.14
Number of metastatic organs
≤2	88	1.30 ± 0.39	0.0–28.27	0.064 c
>2	26	3.25 ± 1.38	0.0–26.14

^a Standard error. ^b TNM staging system. ^c Calculated by the “Mann–Whitney U test”. ^d Calculated by the “Jonckheere-Terpstra Test”. ^e Eastern Cooperative Oncology Group Performance Status.